Home › Compound Library › Erenumab (Aimovig)

Erenumab (Aimovig)

Biologicprescriptionsubcutaneous · inferred

Fully human IgG2 monoclonal antibody targeting the calcitonin-gene-related-peptide (CGRP) receptor; approved for migraine prevention. 70 mg or 140 mg SC monthly. Exhibits biphasic disposition with terminal half-life ~28 days. SC bioavailability ~82%. Notable constipation signal and rare hypertension reports.

Projected serum levels — 70 mg, custom (shown daily)

Erenumab (Aimovig)
Erenumab (Aimovig) modeled serum levels, 70 mg custom (shown daily) over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 79 days. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 79
Erenumab (Aimovig) modeled serum levels with a loading dose of 210 mg, then 70 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 1.3k 2.5k 3.8k 5k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 70 mg custom (shown daily) (subcutaneous).

Loading schedule: 210 mg on day 1, then 70 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~79 days: peak ≈ 2.7k mg, trough ≈ 2.7k mg body load. Population-based estimate over 121 days for a 70 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Biologic
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
28 days
Common dose
70 mg
Suggested maximum
140 mg/day
Reference dose range
35–140 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
70 mg sc — Cmax 6.1 mg/L at 144 h

Documented interactions

  • watch
    Atogepant (Qulipta) + Erenumab (Aimovig) Stacked effects

    Atogepant (Qulipta) and Erenumab (Aimovig) both push the cgrp receptor in the same direction.

  • watch
    Eptinezumab (Vyepti) + Erenumab (Aimovig) Stacked effects

    Eptinezumab (Vyepti) and Erenumab (Aimovig) both push the cgrp receptor in the same direction.

  • watch
    Rimegepant (Nurtec ODT) + Erenumab (Aimovig) Stacked effects

    Erenumab (Aimovig) and Rimegepant (Nurtec ODT) both push the cgrp receptor in the same direction.

  • watch
    Ubrogepant (Ubrelvy) + Erenumab (Aimovig) Stacked effects

    Erenumab (Aimovig) and Ubrogepant (Ubrelvy) both push the cgrp receptor in the same direction.

Serum checks 4 modeled interaction pairings for erenumab (aimovig) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects Vu T et al. · Pharmaceutical Research, 2017 DOI

    PK/PD study characterizing erenumab's target engagement kinetics and exposure-response relationship via capsaicin-CGRP assay.

  2. A controlled trial of erenumab for episodic migraine (STRIVE) Goadsby PJ et al. · New England Journal of Medicine, 2017 DOI

    STRIVE phase 3 trial demonstrating erenumab 70 mg and 140 mg monthly significantly reduced migraine days in episodic migraine.

2 published studies referenced in the app, each with a plain-language summary.